US5705334A
(en)
|
1988-09-22 |
1998-01-06 |
Massachusetts Institute Of Technology |
Uses for DNA structure-specific recognition protein
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
US5747469A
(en)
*
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
AU663702B2
(en)
|
1991-03-06 |
1995-10-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the selective inhibition of gene expression
|
US6495348B1
(en)
|
1993-10-07 |
2002-12-17 |
Regents Of The University Of Minnesota |
Mitomycin biosynthetic gene cluster
|
US6524812B1
(en)
|
1993-10-07 |
2003-02-25 |
Regents Of The University Of Minnesota |
Genes encoding resistance to DNA alkylating agents
|
US20060275261A1
(en)
*
|
1993-10-25 |
2006-12-07 |
Canji, Inc. |
Adenoviral vectors having a protein IX deletion
|
ATE314482T1
(de)
*
|
1993-10-25 |
2006-01-15 |
Canji Inc |
Rekombinante adenoviren-vektor und verfahren zur verwendung
|
US20050031590A9
(en)
*
|
1993-10-25 |
2005-02-10 |
Richard Gregory |
Adenoviral vectors having a protein IX deletion
|
US20010006629A1
(en)
*
|
1993-10-25 |
2001-07-05 |
Richard J. Gregory |
Recombinant adenoviral vector and methods of use
|
US20020010144A1
(en)
*
|
1994-04-29 |
2002-01-24 |
Robert Sobol |
Enhancing the sensitivity of tumor cells to therapies
|
US6638762B1
(en)
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
FR2729295A1
(fr)
*
|
1995-01-17 |
1996-07-19 |
Rhone Poulenc Rorer Sa |
Traitement therapeutique combine des pathologies hyperproliferatives
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US7163925B1
(en)
|
1995-07-17 |
2007-01-16 |
Board Of Regents, The University Of Texas System |
p16 expression constructs and their application in cancer therapy
|
KR19990029028A
(ko)
|
1995-07-17 |
1999-04-15 |
파라비 레이 |
p16 발현 작제물 및 암 치료에서의 이의 용도
|
US5763415A
(en)
|
1995-08-03 |
1998-06-09 |
John Hopkins University School Of Medicine |
Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
|
AU721860B2
(en)
*
|
1995-08-30 |
2000-07-13 |
La Jolla Institute For Allergy And Immunology |
Therapy for cellular accumulation in chronic inflammatory diseases
|
JPH11513390A
(ja)
*
|
1995-10-06 |
1999-11-16 |
アーチ デベロップメント コーポレイション |
細胞殺傷のウイルス増強のための方法および組成物
|
CA2238829A1
(en)
*
|
1995-11-30 |
1997-06-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the diagnosis and treatment of cancer
|
EP1724350A1
(en)
*
|
1995-11-30 |
2006-11-22 |
The Board Of Regents, The University Of Texas System |
Method and compositions for the diagnosis and treatment of cancer
|
US5952221A
(en)
*
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
WO1997039135A1
(en)
|
1996-04-17 |
1997-10-23 |
Board Of Regents, The University Of Texas System |
Enhanced expression of transgenes
|
US6054467A
(en)
*
|
1996-07-05 |
2000-04-25 |
Sidney Kimmel Cancer Center |
Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
US20040023375A1
(en)
*
|
2002-07-30 |
2004-02-05 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
|
AU3731397A
(en)
*
|
1996-07-18 |
1998-02-10 |
Arch Development Corporation |
Methods and compositions for modulation of growth response
|
US5958892A
(en)
*
|
1996-07-30 |
1999-09-28 |
Board Of Regents, The University Of Texas System |
2-methoxyestradiol-induced apoptosis in cancer cells
|
IL130009A0
(en)
*
|
1996-11-18 |
2000-02-29 |
Univ Mcgill |
Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
|
US6183752B1
(en)
*
|
1997-02-05 |
2001-02-06 |
Pasteur Merieux Serums Et Vaccins |
Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
|
US20030060434A1
(en)
*
|
1997-02-18 |
2003-03-27 |
Loretta Nielsen |
Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
|
US20030064949A1
(en)
*
|
1998-02-17 |
2003-04-03 |
Loretta Nielsen |
Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
|
BR9807418A
(pt)
*
|
1997-02-18 |
2002-01-22 |
Canji Inc |
Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
|
US6642045B1
(en)
|
1997-04-14 |
2003-11-04 |
Breonics, Inc. |
System for exsanguinous metabolic support of an organ or tissue
|
US6020191A
(en)
*
|
1997-04-14 |
2000-02-01 |
Genzyme Corporation |
Adenoviral vectors capable of facilitating increased persistence of transgene expression
|
KR19980077401A
(ko)
*
|
1997-04-18 |
1998-11-16 |
문우철 |
와일드타입 p53 유전자벡터와 양이온성 리포솜을 함유하는 암의 유전자 치료제
|
US20050096288A1
(en)
*
|
1997-06-13 |
2005-05-05 |
Aragene, Inc. |
Lipoproteins as nucleic acid vectors
|
US6635623B1
(en)
*
|
1997-06-13 |
2003-10-21 |
Baylor College Of Medicine |
Lipoproteins as nucleic acid vectors
|
US6749863B1
(en)
*
|
1997-11-19 |
2004-06-15 |
Georgetown University |
Targeted liposome gene delivery
|
US6841538B1
(en)
|
1998-04-22 |
2005-01-11 |
Inex Pharmaceuticals Corporation |
Combination therapy using nucleic acids and radio therapy
|
US6841537B1
(en)
*
|
1998-04-22 |
2005-01-11 |
Protiva Biotherapeutics Inc. |
Combination therapy using nucleic acids and conventional drugs
|
US5972640A
(en)
*
|
1998-05-12 |
1999-10-26 |
The Regents Of The University Of California |
Methods for identifying antimitotic agents
|
AU771224B2
(en)
|
1998-07-13 |
2004-03-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
AU5817299A
(en)
*
|
1998-09-10 |
2000-04-03 |
Uab Research Foundation, The |
Adenoviral vector encoding pro-apoptotic bax gene and uses thereof
|
US6649158B1
(en)
*
|
1998-10-15 |
2003-11-18 |
Canji, Inc. |
Methods and compositions to induce antitumor response
|
US7094533B1
(en)
*
|
1999-01-21 |
2006-08-22 |
Board Of Regents Of The University Of Nebraska |
Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
|
JP4799736B2
(ja)
*
|
1999-02-22 |
2011-10-26 |
ジョージタウン・ユニバーシティ |
全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
|
WO2000050584A2
(en)
*
|
1999-02-24 |
2000-08-31 |
University Of Iowa Research Foundation |
Methods and compositions for enhancing in vivo gene delivery/expression
|
EP1165144A2
(en)
*
|
1999-03-15 |
2002-01-02 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
US20070166292A1
(en)
*
|
1999-04-14 |
2007-07-19 |
Breonics, Inc. |
System for exsanguinous metabolic support of an organ or tissue
|
US20040038193A1
(en)
*
|
1999-04-14 |
2004-02-26 |
Breonics, Inc. |
System for exsanguinous metabolic support of an organ or tissue
|
AU4345400A
(en)
*
|
1999-04-14 |
2000-11-14 |
Breonics, Inc. |
System for exsanguinous metabolic support of an organ or tissue
|
EP1916258B1
(en)
|
1999-08-09 |
2014-04-23 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
|
US6734192B1
(en)
|
1999-08-23 |
2004-05-11 |
Mp-1 Inc. |
Treatment of viral infections
|
JP5557974B2
(ja)
*
|
1999-10-07 |
2014-07-23 |
アグイラ−コルドバ,カルロス,エストアルド |
遺伝子治療による固体腫瘍及び転移の治療方法
|
US20040266834A1
(en)
*
|
1999-10-14 |
2004-12-30 |
Copland John A. |
Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
|
US6511676B1
(en)
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
US7048920B2
(en)
*
|
2000-03-24 |
2006-05-23 |
Cell Genesys, Inc. |
Recombinant oncolytic adenovirus for human melanoma
|
US6911200B2
(en)
*
|
2000-03-24 |
2005-06-28 |
Cell Genesys, Inc. |
Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
|
US7306902B2
(en)
*
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
NZ525552A
(en)
|
2000-11-09 |
2005-04-29 |
Neopharm Inc |
SN-38 lipid complexes with cardiolipin and methods of use for the treatment of cancers and multiple sclerosis
|
EP1404359A2
(en)
*
|
2000-12-07 |
2004-04-07 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US20030138405A1
(en)
*
|
2001-04-17 |
2003-07-24 |
Juan Fueyo |
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
US20040086888A1
(en)
*
|
2001-10-18 |
2004-05-06 |
Kornblith Paul L |
Method for tandem genomic/proteomic analysis of proliferating cells
|
US20040028616A1
(en)
*
|
2002-02-14 |
2004-02-12 |
Knight J. Vernon |
Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
|
WO2003075952A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
KR100492016B1
(ko)
*
|
2002-04-11 |
2005-05-30 |
학교법인고려중앙학원 |
안티센스 텔로머라제 생산하는 아데노바이러스 Ad-OA 와항암제 시스플라틴을 이용한 항암 치료 방법
|
EP1496897A4
(en)
|
2002-04-12 |
2006-05-10 |
Merck & Co Inc |
INHIBITORS OF TYROSINE KINASES
|
CA2480325A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Solid forms of salts with tyrosine kinase activity
|
KR20030085421A
(ko)
*
|
2002-04-30 |
2003-11-05 |
신득용 |
p53 또는 p21 유전자 변이에 의해 p53 또는 p21유전자 기능을 상실한 암의 치료를 위한 액틴 저해제를포함하는 약학 조성물
|
US20030219421A1
(en)
*
|
2002-05-23 |
2003-11-27 |
University Of Medicine & Dentistry Of New Jersey |
Calbindin-D28k protection against glucocorticoid induced cell death
|
DK2269656T3
(da)
|
2002-07-15 |
2014-11-03 |
Univ Texas |
Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
|
US7364727B2
(en)
*
|
2002-07-22 |
2008-04-29 |
Cell Genesys, Inc. |
Metastatic colon cancer specific promoter and uses thereof
|
CA2494061C
(en)
*
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
EP1551824B1
(en)
*
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
US20050032728A1
(en)
*
|
2002-12-17 |
2005-02-10 |
Sidney Kimmel Cancer Center |
Tumor suppression through bicistronic co-expression of p53 and p14ARF
|
BRPI0408063A
(pt)
*
|
2003-03-03 |
2006-02-14 |
Univ Texas |
métodos e composições envolvendo mda-7
|
WO2008109433A2
(en)
|
2007-03-02 |
2008-09-12 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
WO2004092396A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Flap endonuclease 1 (fen1) regulatory sequences and uses thereof
|
WO2004092397A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Tmprss2 regulatory sequences and uses thereof
|
WO2005012407A2
(en)
*
|
2003-06-30 |
2005-02-10 |
Canji, Inc. |
Polymer encapsulation of adenoviruses
|
EP2075340A3
(en)
|
2003-09-30 |
2009-07-08 |
Sbarro Health Research Organization |
Gene modulation by RB2/p 130 expression
|
DE10354060A1
(de)
|
2003-11-19 |
2005-06-02 |
Merck Patent Gmbh |
Pyrrolderivate
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
DE10356579A1
(de)
|
2003-12-04 |
2005-07-07 |
Merck Patent Gmbh |
Aminderivate
|
KR101535395B1
(ko)
|
2004-01-22 |
2015-07-08 |
유니버시티 오브 마이애미 |
국소용 코-엔자임 큐10 제형 및 그의 사용 방법
|
WO2005082422A1
(en)
*
|
2004-02-24 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Combination of ad-p53 and chemotherapy for the treatment of tumours
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
WO2005107474A2
(en)
*
|
2004-04-30 |
2005-11-17 |
Introgen Therapeutics, Inc. |
Oncolytic adenovirus armed with therapeutic genes
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
JP5735724B2
(ja)
*
|
2004-11-08 |
2015-06-17 |
インスメッド, インコーポレイテッド |
腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
EP1827487A2
(en)
*
|
2004-11-17 |
2007-09-05 |
Board of Regents, The University of Texas System |
Cancer immunotherapy incorporating p53
|
US20070009484A1
(en)
*
|
2005-02-08 |
2007-01-11 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving MDA-7 for the treatment of cancer
|
DE102005016634A1
(de)
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
AU2006239632B2
(en)
|
2005-04-25 |
2012-03-15 |
Merck Patent Gmbh |
Novel AZA- heterocycles serving as kinase inhibitors
|
WO2006124700A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
DE102005027169A1
(de)
|
2005-06-13 |
2006-12-14 |
Merck Patent Gmbh |
Tetrahydrochinolinderivate
|
EP1929306A4
(en)
*
|
2005-09-01 |
2009-11-11 |
Precision Therapeutics Inc |
CHEMOSENSIBLE ASSAYS, THE TUMOR CELLS WITH PERSISTENT PHENOTYPICAL CHARACTERISTICS
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
DE102005061840A1
(de)
|
2005-12-23 |
2007-06-28 |
Merck Patent Gmbh |
Triazolderivate
|
WO2007090125A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Introgen Therapeutics, Inc. |
Prognostic factors for anti-hyperproliferative disease gene therapy
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US9037230B2
(en)
*
|
2006-03-03 |
2015-05-19 |
Oncosec Medical Incorporated |
Method and device for treating microscopic tumors remaining in tissues following surgical resection
|
US8426387B2
(en)
*
|
2006-03-31 |
2013-04-23 |
Stephen Carper |
Treatments for cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
CA2673683C
(en)
|
2007-01-11 |
2014-07-29 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
CA2939778C
(en)
*
|
2007-01-31 |
2019-01-29 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
DE102007008419A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
DE102007013854A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
DE102007013855A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydrochinoline
|
DE102007013856A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydropyrrolochinoline
|
BRPI0809366B8
(pt)
|
2007-03-28 |
2021-05-25 |
Harvard College |
polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
|
DE102007028515A1
(de)
|
2007-06-21 |
2008-12-24 |
Merck Patent Gmbh |
6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
DE102007047737A1
(de)
|
2007-10-05 |
2009-04-30 |
Merck Patent Gmbh |
Piperidin- und Piperazinderivate
|
DE102007047738A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Imidazolderivate
|
DE102007047735A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Thiazolderivate
|
DE102007049451A1
(de)
|
2007-10-16 |
2009-04-23 |
Merck Patent Gmbh |
5-Cyano-thienopyridine
|
JP5809415B2
(ja)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ,インコーポレーテッド |
抗vegf抗体の組成物および方法
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
DE102008005493A1
(de)
|
2008-01-22 |
2009-07-23 |
Merck Patent Gmbh |
4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
|
DK2245464T3
(en)
|
2008-01-25 |
2017-02-20 |
Multivir Inc |
P53 BIOMARKETS
|
DE102008017853A1
(de)
|
2008-04-09 |
2009-10-15 |
Merck Patent Gmbh |
Thienopyrimidine
|
MX2010011168A
(es)
|
2008-04-15 |
2010-12-21 |
Pharmacyclics Inc |
Inhibidores selectivos de histona-desacetilasa.
|
DE102008025751A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
|
DE102008027574A1
(de)
|
2008-06-10 |
2009-12-17 |
Merck Patent Gmbh |
Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
|
DE102008031517A1
(de)
|
2008-07-03 |
2010-01-07 |
Merck Patent Gmbh |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
DE102008059578A1
(de)
|
2008-11-28 |
2010-06-10 |
Merck Patent Gmbh |
Benzo-Naphtyridin Verbindungen
|
DE102009005193A1
(de)
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
CN102365271B
(zh)
|
2009-04-02 |
2014-05-14 |
默克专利有限公司 |
作为自分泌运动因子抑制剂的杂环化合物
|
HRP20212024T1
(hr)
*
|
2009-05-02 |
2022-04-01 |
Genzyme Corporation |
Genska terapija za neurodegenerativne poremećaje
|
DE102009019962A1
(de)
|
2009-05-05 |
2010-11-11 |
Merck Patent Gmbh |
3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
DE102009033208A1
(de)
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
DE102009033392A1
(de)
|
2009-07-16 |
2011-01-20 |
Merck Patent Gmbh |
Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
|
ES2745255T3
(es)
|
2009-08-26 |
2020-02-28 |
Alberta Health Services |
Derivados de colchicina novedosos, métodos y usos de los mismos
|
DE102009049211A1
(de)
|
2009-10-13 |
2011-04-28 |
Merck Patent Gmbh |
Sulfoxide
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
p53活性を増大する置換ピペリジン及びその使用
|
KR20130025860A
(ko)
|
2009-11-07 |
2013-03-12 |
메르크 파텐트 게엠베하 |
Tgf-베타 수용체 키나아제 저해제로서의 헤테로아릴아미노퀴놀린
|
DE102009060175A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
|
DE102009060174A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
EA201290919A1
(ru)
|
2010-03-16 |
2013-03-29 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Индазольные соединения и их применение
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
CN103282510A
(zh)
|
2010-08-13 |
2013-09-04 |
爱勒让治疗公司 |
拟肽大环化合物
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DE102010048374A1
(de)
|
2010-10-13 |
2012-04-19 |
Merck Patent Gmbh |
Pyrrolidinone als MetAP-2 Inhibitoren
|
CN108404115A
(zh)
|
2010-10-15 |
2018-08-17 |
纽约市哥伦比亚大学理事会 |
肥胖症-相关的基因和它们的蛋白和其用途
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
WO2013149194A1
(en)
|
2012-03-29 |
2013-10-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
EP2635299B1
(en)
|
2010-11-02 |
2019-07-31 |
The Trustees of Columbia University in the City of New York |
Methods for treating hair loss disorders
|
DE102010050558A1
(de)
|
2010-11-05 |
2012-05-10 |
Merck Patent Gmbh |
1H-Pyrrolo[2,3-b]pyridinderivate
|
DE102010053347A1
(de)
|
2010-12-03 |
2012-06-06 |
Merck Patent Gmbh |
3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
DE102011008352A1
(de)
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
DE102011009961A1
(de)
|
2011-02-01 |
2012-08-02 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
SG194105A1
(en)
|
2011-05-23 |
2013-11-29 |
Merck Patent Gmbh |
Pyridine-and pyrazine derivatives
|
DE102011105469A1
(de)
|
2011-06-24 |
2012-12-27 |
Merck Patent Gmbh |
7-Azaindolderivate
|
WO2013022519A1
(en)
|
2011-08-10 |
2013-02-14 |
Merck Patent Gmbh |
Pyrido-pyrimidine derivatives
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
BR112014009418A2
(pt)
|
2011-10-18 |
2017-04-18 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
SI2812337T1
(sl)
|
2012-02-09 |
2017-01-31 |
Merck Patent Gmbh |
Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
|
US8987414B2
(en)
|
2012-02-15 |
2015-03-24 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
EP2822572B1
(en)
|
2012-02-15 |
2020-06-10 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US9347065B2
(en)
|
2012-03-29 |
2016-05-24 |
International Aids Vaccine Initiative |
Methods to improve vector expression and genetic stability
|
US20150190532A1
(en)
|
2012-04-04 |
2015-07-09 |
The Trustees Of Columbia University In The City Of New York |
Smooth muscle specific inhibition for anti-restenotic therapy
|
DE102012006884A1
(de)
|
2012-04-04 |
2013-10-10 |
Merck Patent Gmbh |
Cyclische Amide als MetAP-2 Inhibitoren
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CN115414384A
(zh)
|
2012-09-04 |
2022-12-02 |
埃莱森制药有限责任公司 |
用顺铂脂质复合物预防癌症的肺部复发
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
BR112015006990A2
(pt)
|
2012-09-28 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de pelo menos um composto
|
DE102012019369A1
(de)
|
2012-10-02 |
2014-04-03 |
Merck Patent Gmbh |
7-Azaindolderivat
|
EA034163B1
(ru)
|
2012-10-17 |
2020-01-13 |
Васкьюлар Байодженикс Лтд. |
Конструкция нуклеиновой кислоты, содержащая промотор, специфичный для эндотелиальных клеток, и их противоопухолевое применение
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN104812384B
(zh)
|
2012-11-01 |
2020-09-18 |
爱勒让治疗公司 |
二取代的氨基酸及其制备和使用方法
|
PT2925888T
(pt)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Composições e métodos para tratamento do cancro
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
KR102089121B1
(ko)
|
2013-03-14 |
2020-03-13 |
더 솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양살상형 아데노바이러스 조성물
|
KR20150129847A
(ko)
|
2013-03-15 |
2015-11-20 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
융합 단백질 및 이들의 방법
|
CN105307656B
(zh)
|
2013-06-06 |
2019-02-19 |
利德发现中心有限责任公司 |
巨噬细胞刺激1受体mst1r的喹啉抑制剂
|
RU2534802C1
(ru)
*
|
2013-08-01 |
2014-12-10 |
Александр Николаевич Гребенюк |
Способ моделирования сочетанных радиационных поражений, включающих общее гамма-и местное бета-облучение
|
RU2527148C1
(ru)
*
|
2013-08-01 |
2014-08-27 |
Александр Николаевич Гребенюк |
Способ моделирования сочетанных радиационных поражений, включающих общее гамма- и местное рентгеновское облучение
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
PT3712174T
(pt)
|
2013-12-24 |
2022-05-27 |
Janssen Pharmaceutica Nv |
Anticorpos e fragmentos anti-vista
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US11123426B2
(en)
|
2014-06-11 |
2021-09-21 |
The Trustees Of Dartmouth College |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
EP4159741A1
(en)
|
2014-07-16 |
2023-04-05 |
ModernaTX, Inc. |
Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
|
SG11201702175YA
(en)
|
2014-09-24 |
2017-04-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and formulations thereof
|
CA2961258A1
(en)
|
2014-09-24 |
2016-03-31 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
EP3226900A4
(en)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
EP3237452A4
(en)
|
2014-12-23 |
2018-12-05 |
The Trustees of Columbia University in the City of New York |
Fusion proteins and methods thereof
|
SG11201707750YA
(en)
|
2015-03-20 |
2017-10-30 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP3313882B1
(en)
|
2015-06-24 |
2020-03-11 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
EP3702470A3
(en)
|
2015-09-09 |
2020-10-07 |
The Trustees of Columbia University in the City of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
CN108368161A
(zh)
|
2015-09-10 |
2018-08-03 |
艾瑞朗医疗公司 |
作为mcl-1调节剂的拟肽大环化合物
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
CN108699566B
(zh)
|
2016-02-23 |
2023-06-30 |
萨克生物研究学院 |
对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
|
CA3013637A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
US11525000B2
(en)
|
2016-04-15 |
2022-12-13 |
Immunext, Inc. |
Anti-human VISTA antibodies and use thereof
|
US11066396B2
(en)
|
2016-06-23 |
2021-07-20 |
Merck Sharp & Dohme Corp. |
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
EP3532082A4
(en)
|
2016-12-12 |
2020-08-26 |
Salk Institute for Biological Studies |
SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
|
CN110996958B
(zh)
|
2017-08-16 |
2023-05-12 |
默克专利股份有限公司 |
包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2019207167A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Telethon |
Therapy of sulfatase deficiencies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CN110055227A
(zh)
*
|
2019-03-13 |
2019-07-26 |
中国人民解放军第四军医大学 |
用于增生性瘢痕治疗的野生型p53腺病毒及纯化的制备方法
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|
US20240116945A1
(en)
|
2022-09-02 |
2024-04-11 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
US20240208987A1
(en)
|
2022-10-25 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
US20240207425A1
(en)
|
2022-12-14 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|